FDA Approves Reduced Monitoring Time for First Two IMDELLTRA Doses in ES-SCLC
核心洞察
The FDA approved an update to the IMDELLTRA prescribing information cutting required monitoring for the first two infusions from 22-24 hours to 6-8 hours.
Patients must still receive a follow-up assessment, including vital signs, the day after each of the first two doses on Cycle 1 Days 2 and 9.
Amgen said the change may reduce treatment complexity for community oncology practices, where an estimated 80% to 85% of US cancer patients receive care.
Amgen announced that the U.S. Food and Drug Administration has approved an update to the IMDELLTRA (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting. Under the revised label, patients receiving IMDELLTRA should now be monitored for 6 to 8 hours from the start of their first two infusions, compared with the previously recommended 22 to 24 hours.
The scope of the label update was limited to the first two doses, administered on Cycle 1 Day 1 and Cycle 1 Day 8. Patients will also receive a follow-up assessment, including vital signs, the day after each of these first two doses, on Cycle 1 Days 2 and 9.
Rationale for the Change
For people living with extensive-stage small cell lung cancer (搜索) (ES-SCLC), the change could mean substantially less time spent in a healthcare setting during the initial treatment period. The updated requirement may also reduce treatment complexity for community oncology practices, where an estimated 80% to 85% of U.S. cancer patients receive care.
"People being treated for small cell lung cancer (搜索) are already navigating an aggressive and difficult-to-treat disease, and the time required to receive and monitor treatment can add to that burden for both patients and care centers," said Jay Bradner, M.D., executive vice president, Research and Development, Artificial Intelligence and Data at Amgen. "This approval is an important step in simplifying care for people living with and treating ES-SCLC. Reducing monitoring to 6-8 hours for the initial doses may help address practical barriers associated with administering IMDELLTRA and enable more patients to receive care closer to home."
David M. Waterhouse, MD, MPH, FASCO, a medical oncologist/hematologist at Oncology Hematology Care in Cincinnati, Ohio, framed the update in terms of community practice logistics. "In community oncology, we care for patients where they live, and for people living with small cell lung cancer (搜索), that matters," he said. "These patients are often very sick, and traveling long distances or spending extended time in a healthcare setting can be difficult for them and their families. Reducing the required monitoring period may make IMDELLTRA more feasible to administer in community practices, helping more patients receive treatment in their local care network and spend less time away from their support systems."
What Remains Unchanged
Beyond the first two doses and the addition of the day-after assessment, the monitoring and supportive care recommendations remain unchanged. Patients should be monitored for 6 to 8 hours following the third dose (Cycle 1 Day 15) and throughout Cycle 2, decreasing to 3 to 4 hours for Cycles 3-4 and 2 hours for Cycle 5 and subsequent doses.
It is recommended that patients remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from the start of the infusion with IMDELLTRA following the Cycle 1 Day 1 and Cycle 1 Day 8 doses, accompanied by a caregiver. Patients and caregivers should be informed of the signs and symptoms of cytokine release syndrome (CRS) and ICANS prior to discharge, and patients should be well hydrated before administration.
Mechanism and Safety Profile
IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen researchers to bind to both DLL3 (搜索) on tumor cells and CD3 (搜索) on T cells, thereby activating T cells to kill DLL3-expressing SCLC cells, resulting in the formation of a cytolytic synapse with lysis of the cancer cell. DLL3 is expressed on the surface of SCLC cells in approximately 85% to 96% of patients with SCLC, but is minimally expressed on healthy cells.
The agent carries boxed warnings for CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). In the pooled safety population of 473 patients with small cell lung cancer (搜索) across the DeLLphi-300, DeLLphi-301 and DeLLphi-304 trials, CRS occurred in 57% of patients (39% Grade 1, 15% Grade 2, 1.7% Grade 3, 0.2% Grade 4), and neurologic toxicity occurred in 65%, with Grade 3 or higher events in 7% including fatal events in 0.2%. The incidence of signs and symptoms consistent with ICANS was 10%.
Among the 268 patients who experienced CRS, 73% had CRS after the first dose, 60% after the second dose, and 15% following the third or later dose. Following the Cycle 1 Day 1, Day 8 and Day 15 infusions, 24%, 8% and 1% of patients experienced Grade ≥2 CRS, respectively. The median time to onset of all-grade CRS from the most recent dose was 16 hours (range: start of infusion to 15 days).
The most common (≥20%) adverse reactions were CRS (57%), fatigue (48%), decreased appetite (38%), dysgeusia (34%), pyrexia (33%), constipation (31%), musculoskeletal pain (31%) and nausea (25%). The most common (≥5%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes (43%), decreased sodium (12%), decreased total neutrophils (9%) and increased uric acid (6%).
Indication and Supporting Data
IMDELLTRA is indicated for the treatment of adult patients with ES-SCLC with disease progression on or after platinum-based chemotherapy. The FDA previously granted traditional approval in November 2025 based on the Phase 3 DeLLphi-304 trial (NCT05740566), in which tarlatamab produced a median overall survival of 13.6 months (95% CI, 11.1-not evaluable) versus 8.3 months (95% CI, 7.0-10.2) with chemotherapy.
Amgen recently announced landmark positive topline overall survival data from the Phase 3 DeLLphi-305 study evaluating tarlatamab plus durvalumab as first-line maintenance therapy in ES-SCLC. Reduced post-infusion monitoring timing is being evaluated in several ongoing studies across indications and lines of therapy, which the company said will continue to inform the potential to further reduce monitoring approaches in the future.
Disease Burden
SCLC is one of the most aggressive and devastating forms of solid tumor cancer. Each year, SCLC accounts for approximately 13-15% of more than 2.6 million cases of lung cancer diagnosed worldwide. Despite initial high response rates to first-line platinum-based chemotherapy, most patients quickly relapse within months and require subsequent treatment options. ES-SCLC is an aggressive form of lung cancer in which most patients experience disease progression following first-line treatment.